Your browser doesn't support javascript.
loading
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Sequist, Lecia V; Han, Ji-Youn; Ahn, Myung-Ju; Cho, Byoung Chul; Yu, Helena; Kim, Sang-We; Yang, James Chih-Hsin; Lee, Jong Seok; Su, Wu-Chou; Kowalski, Dariusz; Orlov, Sergey; Cantarini, Mireille; Verheijen, Remy B; Mellemgaard, Anders; Ottesen, Lone; Frewer, Paul; Ou, Xiaoling; Oxnard, Geoffrey.
Afiliación
  • Sequist LV; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Han JY; Center for Lung Cancer, National Cancer Center, Goyang, South Korea.
  • Ahn MJ; Samsung Medical Center, Sungkyunkwan University, School of Medicine, Seoul, South Korea.
  • Cho BC; Department of Medicine, Yonsei Cancer Center, Seoul, South Korea.
  • Yu H; Department of Medical Oncology, Memorial Sloan Kettering Cancer Centre, New York, NY, USA.
  • Kim SW; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
  • Yang JC; Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan.
  • Lee JS; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul, South Korea.
  • Su WC; Department of Internal Medicine, National Cheng Kung University Hospital, Tainan City, Taiwan.
  • Kowalski D; Department of Lung Cancer and Thoracic Oncology, Centrum Onkologii, Instytut im Marii Sklodowskiej-Curie, Warsaw, Poland.
  • Orlov S; BioEq, Saint Petersburg, Russia.
  • Cantarini M; Oncology R&D, AstraZeneca, Cambridge, UK.
  • Verheijen RB; Oncology R&D, AstraZeneca, Cambridge, UK.
  • Mellemgaard A; Oncology R&D, AstraZeneca, Cambridge, UK.
  • Ottesen L; Oncology R&D, AstraZeneca, Cambridge, UK.
  • Frewer P; Oncology Biometrics, AstraZeneca, Cambridge, UK.
  • Ou X; Oncology Biometrics, AstraZeneca, Cambridge, UK.
  • Oxnard G; Department of Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: geoffrey_oxnard@dfci.harvard.edu.
Lancet Oncol ; 21(3): 373-386, 2020 03.
Article en En | MEDLINE | ID: mdl-32027846
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Amplificación de Genes / Carcinoma de Pulmón de Células no Pequeñas / Resistencia a Antineoplásicos / Proteínas Proto-Oncogénicas c-met / Neoplasias Pulmonares / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Amplificación de Genes / Carcinoma de Pulmón de Células no Pequeñas / Resistencia a Antineoplásicos / Proteínas Proto-Oncogénicas c-met / Neoplasias Pulmonares / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos